1. Home
  2. SCWO vs PPBT Comparison

SCWO vs PPBT Comparison

Compare SCWO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$2.47

Market Cap

45.2M

Sector

Utilities

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$4.10

Market Cap

45.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCWO
PPBT
Founded
2021
2010
Country
United States
Israel
Employees
27
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.2M
45.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SCWO
PPBT
Price
$2.47
$4.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
42.7K
68.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5,945.19
N/A
Revenue Next Year
$106.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.41
52 Week High
$3.55
$5.18

Technical Indicators

Market Signals
Indicator
SCWO
PPBT
Relative Strength Index (RSI) 46.23 67.45
Support Level $2.33 $0.57
Resistance Level $2.83 $5.18
Average True Range (ATR) 0.20 0.34
MACD -0.03 0.10
Stochastic Oscillator 28.69 68.97

Price Performance

Historical Comparison
SCWO
PPBT

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: